A detailed history of Legal & General Group PLC transactions in Mersana Therapeutics, Inc. stock. As of the latest transaction made, Legal & General Group PLC holds 11,097 shares of MRSN stock, worth $20,529. This represents 0.0% of its overall portfolio holdings.

Number of Shares
11,097
Previous 11,097 -0.0%
Holding current value
$20,529
Previous $49,000 55.1%
% of portfolio
0.0%
Previous 0.0%

Shares

20 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 14, 2024

SELL
$2.16 - $5.94 $39,808 - $109,474
-18,430 Reduced 62.42%
11,097 $49,000
Q4 2023

Feb 15, 2024

SELL
$1.11 - $2.34 $26,234 - $55,305
-23,635 Reduced 44.46%
29,527 $68,000
Q3 2023

Nov 14, 2023

SELL
$1.06 - $3.91 $20,855 - $76,929
-19,675 Reduced 27.01%
53,162 $67,000
Q2 2023

Aug 14, 2023

BUY
$3.08 - $9.55 $112,071 - $347,495
36,387 Added 99.83%
72,837 $239,000
Q1 2023

May 15, 2023

BUY
$4.0 - $7.02 $5,044 - $8,852
1,261 Added 3.58%
36,450 $149,000
Q4 2022

Feb 14, 2023

BUY
$5.65 - $7.86 $7,356 - $10,233
1,302 Added 3.84%
35,189 $206,000
Q3 2022

Nov 14, 2022

BUY
$4.63 - $8.0 $10,838 - $18,728
2,341 Added 7.42%
33,887 $229,000
Q2 2022

Aug 22, 2022

BUY
$2.84 - $5.0 $17,752 - $31,255
6,251 Added 24.71%
31,546 $145,000
Q1 2022

May 16, 2022

BUY
$3.74 - $6.63 $676 - $1,200
181 Added 0.72%
25,295 $101,000
Q3 2021

Nov 15, 2021

BUY
$8.56 - $14.47 $95,084 - $160,732
11,108 Added 79.31%
25,114 $236,000
Q2 2021

Aug 12, 2021

BUY
$13.28 - $18.07 $12,071 - $16,425
909 Added 6.94%
14,006 $190,000
Q1 2021

May 17, 2021

SELL
$15.31 - $26.52 $7,777 - $13,472
-508 Reduced 3.73%
13,097 $212,000
Q4 2020

Feb 12, 2021

SELL
$16.84 - $27.59 $1,633 - $2,676
-97 Reduced 0.71%
13,605 $362,000
Q3 2020

Nov 13, 2020

SELL
$16.2 - $25.7 $18,079 - $28,681
-1,116 Reduced 7.53%
13,702 $255,000
Q2 2020

Aug 14, 2020

BUY
$5.24 - $23.4 $52,887 - $236,176
10,093 Added 213.61%
14,818 $347,000
Q1 2020

May 14, 2020

SELL
$4.41 - $9.28 $5,600 - $11,785
-1,270 Reduced 21.18%
4,725 $27,000
Q2 2019

Aug 14, 2019

BUY
$3.84 - $6.4 $15,598 - $25,996
4,062 Added 210.14%
5,995 $24,000
Q2 2018

Aug 10, 2018

SELL
$14.2 - $22.68 $312 - $498
-22 Reduced 1.13%
1,933 $35,000
Q1 2018

May 17, 2018

BUY
$13.56 - $18.48 $16,977 - $23,136
1,252 Added 178.09%
1,955 $31,000
Q4 2017

Feb 13, 2018

BUY
$14.95 - $19.9 $10,509 - $13,989
703
703 $12,000

Others Institutions Holding MRSN

About Mersana Therapeutics, Inc.


  • Ticker MRSN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 97,169,296
  • Market Cap $180M
  • Description
  • Mersana Therapeutics, Inc., a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma. The company also dev...
More about MRSN
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.